GlassScriptPhysician profile
Marvin Mcgowan
NPI 1851382535
$4,326.50
in general payments reported to CMS, 2019-2025
23 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $554 · 2021: $918 · 2022: $587 · 2023: $888 · 2024: $459 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,614.06 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,014.95 | 2019-2025 | Yeztugo |
| Abbvie INC. | $609.85 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $293.27 | 2019-2024 | Pifeltro, Delstrigo |
| Janssen Pharmaceuticals, INC | $85.38 | 2020-2021 | |
| Antares Pharma, INC. | $77.68 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Emd Serono, INC. | $75.16 | 2019 | |
| Hologic Sales and Service, LLC | $67.23 | 2021-2025 | Aptima |
| Theratechnologies INC. | $62.62 | 2019-2021 | |
| Janssen Biotech, INC. | $53.93 | 2022-2023 | Symtuza |
| Otsuka America Pharmaceutical, INC. | $52.04 | 2019-2023 | Abilify Maintena |
| Lilly USA, LLC | $51.34 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.33 | 2021 | |
| Neurocrine Biosciences, INC. | $41.44 | 2019-2021 | |
| Indivior INC. | $33.11 | 2023 | Perseris, Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $26.99 | 2019 | |
| Lundbeck LLC | $20.13 | 2021 | |
| Bausch Health US, LLC | $19.92 | 2019 | |
| Allergan, INC. | $19.54 | 2020 | |
| Halozyme INC | $18.25 | 2023 | |
| Novo Nordisk INC | $16.42 | 2022 | |
| Organon LLC | $16.16 | 2023 | Nexplanon |
| Metuchen Pharmaceuticals | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.